108 results
Page 3 of 6
8-K
EX-99.1
v86yfbnvbkal81c3cd
25 Feb 21
Gossamer Bio Announces Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Update
8:00am
8-K
pp9edofdefo hnqgywox
17 Nov 20
Departure of Directors or Certain Officers
5:13pm
8-K
EX-99.1
rt3 997p0jogvbz
10 Nov 20
Gossamer Bio Announces Third Quarter 2020 Financial Results and Provides Corporate Update
4:14pm
8-K
EX-99.2
7tkjy
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
8-K
EX-99.1
9ufzj
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
8-K
nxdrr3 zbs
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
8-K
EX-99.1
gsmsx2o
11 Aug 20
Gossamer Bio Announces Second Quarter 2020 Financial Results and Provides Corporate Update
4:30pm
8-K
EX-4.1
esbx37egvm09zks
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
EX-1.1
s0c9qa8eoqn
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
EX-4.2
z6l4fy9blsh4fxrpn0x
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
EX-1.2
tanatcnf7ke22zaniw
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
424B5
gu5chpxl0z5mc
19 May 20
Prospectus supplement for primary offering
5:11pm
424B5
1v24hb80cq yheps
19 May 20
Prospectus supplement for primary offering
5:08pm
424B5
x7wj77eafx
18 May 20
Prospectus supplement for primary offering
4:16pm
424B5
yim5 vwm5wem2fmzjosn
18 May 20
Prospectus supplement for primary offering
4:11pm